OR WAIT null SECS
July 10, 2024
In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth's founder and CEO, offers his thoughts surrounding the lack of supply.
Why these programs require a hybrid approach that combines technology and human connection.
July 09, 2024
The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.
An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.
July 08, 2024
Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence
Double-digit, year-on-year growth is now on a six-month streak.
July 05, 2024
An observational, retrospective cohort study undergoes this investigation in individuals 24 years of age or older.
July 04, 2024
The investment is expected to help enhance the company temperature-controlled services in the Netherlands, France, Italy, and Hungary.
July 03, 2024
The Stelara biosimilar will be commercialized by Sandoz, and is expected to launch by February 2025 for multiple indications, including for the treatment of adult patients with active psoriatic arthritis.
The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product.